In vivo imaging of apoptosis by 99mTc-annexin V scintigraphy:: visual analysis in relation to treatment response

被引:99
作者
Kartachova, M
Haas, TLM
Olmos, RAV
Hoebers, FJP
van Zandwijk, N
Verheij, M
机构
[1] Antoni Van Leeuwenhoek Hosp, Netherlands Canc Inst, Dept Radiotherapy, NL-1066 CX Amsterdam, Netherlands
[2] Antoni Van Leeuwenhoek Hosp, Netherlands Canc Inst, Dept Nucl Med, NL-1066 CX Amsterdam, Netherlands
[3] Antoni Van Leeuwenhoek Hosp, Netherlands Canc Inst, Dept Thorac Oncol, NL-1066 CX Amsterdam, Netherlands
关键词
apoptosis; Tc-99m-rh-Annexin V scintigraphy; visual pattern; treatment response;
D O I
10.1016/j.radonc.2004.07.008
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background and purpose: Anticancer therapy induces apoptosis in a dose- and time-dependent fashion. Tc-99m-Hynic-rh-Annexin V scintigraphy (TAVS) enables non-invasive in vivo imaging of treatment-induced apoptosis. We identified the visual patterns of Tc-99m-Hynic-rh-Annexin V tumour uptake and related these to treatment response. Patients and methods: Thirty-three patients with malignant lymphoma (n = 26), leukaemia (n = 1) NSCLC (n = 5), H&NSCC (n = 1), scheduled for radiotherapy (n = 27), platinum-based chemotherapy (n = 5) or concurrent chemoradiation (n = 1), underwent TAVS before and early after the start of treatment. Planar and SPECT images were visually examined to assess changes in tumour Tc-99m-Hynic-rh-Annexin V uptake. Twenty-nine patients were eligible for further analysis. Annexin V uptake before (U-baseline) and early after (U-post) the start of treatment was graded using a four-step scale: 0, absent; 1, weak; 2, moderate and 3, intense. The difference between these values (DeltaU) was calculated and correlated to tumour response after therapy (Spearman rank correlation test). Results: Weak to moderate U-baseline was detected in 13/15 patients with a complete response and U-post was markedly increased in all these cases (DeltaU range 1-3). Partial response (n=7) was associated with weak to moderate U-baseline and a moderately increased U-post (DeltaU range 1-2). In patients with stable disease (n=5), U-baseline was predominantly weak, without considerable changes in uptake after the start of treatment (DeltaU range 0-1). Finally, in case of progressive disease (n=2), either no tumour uptake or a decrease in U-post was detected (DeltaU=-1). A statistically significant correlation was found between changes in Tc-99m-Hynic-rh-Annexin V tumour uptake and clinical response (correlation coefficient=0.62; P<0.001). Conclusions: Complete or partial tumour response was associated with a marked increase of Tc-99m Hynic-rh-Annexin V accumulation early during treatment compared to baseline values. In case of stable or progressive disease, pretreatment scans demonstrated predominantly low Tc-99m Hynic-rh-Annexin V tumour uptake and no significant increase early after treatment. These results indicate that TAVS might be useful as a predictive test for treatment response. (C) 2004 Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码:333 / 339
页数:7
相关论文
共 34 条
[1]   Towards prediction and modulation of treatment response [J].
Bartelink, H ;
Begg, A ;
Martin, JC ;
van Dijk, M ;
van't Veer, L ;
van der Vaart, P ;
Verheij, M .
RADIOTHERAPY AND ONCOLOGY, 1999, 50 (01) :1-11
[2]   In vivo imaging of chemotherapy-induced apoptosis in human cancers [J].
Belhocine, T ;
Steinmetz, N ;
Green, A ;
Rigo, P .
APOPTOSIS: FROM SIGNALING PATHWAYS TO THERAPEUTIC TOOLS, 2003, 1010 :525-529
[3]   The Imaging of apoptosis with the radiolabeled annexin V: Optimal timing for clinical feasibility [J].
Belhocine, T ;
Steinmetz, N ;
Li, C ;
Green, A ;
Blankenberg, FG .
TECHNOLOGY IN CANCER RESEARCH & TREATMENT, 2004, 3 (01) :23-32
[4]  
Belhocine T, 2002, CLIN CANCER RES, V8, P2766
[5]   Apoptosis-modulating agents in combination with radiotherapy-current status and outlook [J].
Belka, C ;
Jendrossek, V ;
Pruschy, M ;
Vink, S ;
Verheij, M ;
Budach, W .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2004, 58 (02) :542-554
[6]   Apoptotic index and bcl-2 expression as prognostic factors in colorectal carcinoma [J].
Bendardaf, R ;
Ristamäki, R ;
Kujari, H ;
Laine, J ;
Lamlum, H ;
Collan, Y ;
Pyrhönen, S .
ONCOLOGY, 2003, 64 (04) :435-442
[7]  
Blankenberg F, 2003, Q J NUCL MED, V47, P337
[8]   In vivo detection and imaging of phosphatidylserine expression during programmed cell death [J].
Blankenberg, FG ;
Katsikis, PD ;
Tait, JF ;
Davis, RE ;
Naumovski, L ;
Ohtsuki, K ;
Kopiwoda, S ;
Abrams, MJ ;
Darkes, M ;
Robbins, RC ;
Maecker, HT ;
Strauss, HW .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1998, 95 (11) :6349-6354
[9]  
de Jong JS, 2000, BRIT J CANCER, V82, P368
[10]  
Dive C, 1992, Semin Cancer Biol, V3, P417